Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 30.85%.

  • Phathom Pharmaceuticals' EBIT Margin rose 4021000.0% to 30.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 145.03%, marking a year-over-year increase of 9509900.0%. This contributed to the annual value of 502.18% for FY2024, which is 240303700.0% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported EBIT Margin of 30.85% as of Q3 2025, which was up 4021000.0% from 151.69% recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' EBIT Margin registered a high of 1373.9% during Q1 2022, and its lowest value of 10245.6% during Q4 2023.
  • For the 4-year period, Phathom Pharmaceuticals' EBIT Margin averaged around 1077.79%, with its median value being 176.0% (2025).
  • As far as peak fluctuations go, Phathom Pharmaceuticals' EBIT Margin tumbled by -107313500bps in 2023, and later skyrocketed by 100453000bps in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' EBIT Margin stood at 485.75% in 2022, then tumbled by -2209bps to 10245.6% in 2023, then surged by 98bps to 200.3% in 2024, then surged by 85bps to 30.85% in 2025.
  • Its EBIT Margin was 30.85% in Q3 2025, compared to 151.69% in Q2 2025 and 276.53% in Q1 2025.